Neulasta has been one of Amgen's (NASDAQ: AMGN)crown jewels for years, but following FDA approval of Mylan's (NASDAQ: MYL)Neulasta biosimilar this week, Amgen could see Neulasta's revenue slow to a trickle. Is Mylan about to deliver a big blow to Amgen's market share? Read on to find out what's at stake for these companies and their investors.
Watch Out Amgen, Here Comes Mylan
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться